SlideShare ist ein Scribd-Unternehmen logo
1 von 22
Downloaden Sie, um offline zu lesen
APEC LSIF training program on Medical
Products Integrity and Supply Chain Security:
Establishment of global SPOC Systems
29 January 2015
François-Xavier Lery, EDQM/Council of Europe
Practical tools and approaches for
SPOCs
François-Xavier Lery © 2015 EDQM, Council of Europe. All rights reserved.
Content
1. Practicalities: appointment, nomination
2. Information sharing between SPOCs
3. Risk communication
François-Xavier Lery © 2015 EDQM, Council of Europe. All rights reserved.
Practicalities of establishment of SPOC
network
• Competent authorities (1 State): identification &
nomination of SPOCs; 1 National SPOC
• Network (directory of contact details SPOCs):
administration & maintenance, confidentiality, updates
• Support tools (SPOC):
• Form/data base information exchange among SPOCs/
periodical reports
• health risk evaluation procedure (suspect product)
• risk communication procedure – awareness campaigns or
about a concrete case
François-Xavier Lery © 2015 EDQM, Council of Europe. All rights reserved.
Context for SPOC appointment
François-Xavier Lery © 2015 EDQM, Council of Europe. All rights reserved.
…Combatting organised crimes requires:
• appropriate powers
• responsibility (data confidentiality)
• security of SPOCs (national /regional
network)
• availability: 24/7/365
• access to information/ data (analyses, data bases
systematic collection, exchange, sharing of
information)
Major role in reduction of health risks;
involvement in investigation & judicial
procedures
SPOC Nomination
• By Ministries or Heads of Directorates or Agencies:
• Fields:
• Regulation for Pharmaceuticals
• Official Medicines Control Laboratories
• Police/ Gendarmerie
• Customs
(officials only)
Note: Industry = reference /contact for support upon request from authorities
(case by case)
• Nomination Letter: to be issued by senior official
• SPOC & deputy SPOC (1 per competent authority)
• 1 National SPOC (international cooperation; link with
national network of SPOC authorities)
François-Xavier Lery © 2015 EDQM, Council of Europe. All rights reserved.
Profile of Nominees
• Depends on job duties/functions of post held (officials involved
in investigations; operational management of cases of crimes
affecting medical products)
• Professional experience
• Contact details of deputy needed
• Agreement to share SPOCs contact details with other SPOC
nominees
• Nomination letter duly signed (original) by Director / Head of
Agency
• Validity period (unlimited or limited or linked to post) of
nomination
François-Xavier Lery © 2015 EDQM, Council of Europe. All rights reserved.
Nomination
• Should authorise to make information available within national
network of SPOCs (administrative procedure)
• SPOCs should be warned about risks and consequences of
non-authorised use of information that should stay within the
SPOCs network, or negligent handling of information shared
through the network
François-Xavier Lery © 2015 EDQM, Council of Europe. All rights reserved.
Content
1. Practicalities: appointment, nomination
2. Information sharing between SPOCs
3. Risk communication
François-Xavier Lery © 2015 EDQM, Council of Europe. All rights reserved.
Receiving & signal handling/collecting
information through SPOCs network
1. Signals: handling – see SPOCs toolkit
2. Rapid Alert : suspect medical product
Form PIC/S (Pharmaceutical Inspection Convention
Pharmaceutical Inspection Cooperation Scheme)
Health risk evaluation
Communication (professionals / public)
3. Closed cases:
Periodic trend analyses (data/signals, reports, results of
preventive /coercive measures) - databases e.g. EDQM’s
KnowX or other international organisations
4. Feed-back
François-Xavier Lery © 2015 EDQM, Council of Europe. All rights reserved.
Receiving & signal handling/collecting
information through SPOCs (network)
Rapid Alert : suspect medical product
Example: form PIC/S (Pharmaceutical Inspection
Convention Pharmaceutical Inspection Cooperation
Scheme)
François-Xavier Lery © 2015 EDQM, Council of Europe. All rights reserved.
François-Xavier Lery © 2015 EDQM, Council of Europe. All rights reserved.
François-Xavier Lery © 2015 EDQM, Council of Europe. All rights reserved.
Receiving & signal handling/collecting
information through SPOC network
Closed case (no Rapid Alert):
Periodic trend analyses (data/signals, reports, results
of preventive /coercive measures) - databases e.g.
EDQM’s KnowX or other international organisations
• Medical product description (genuine) – suspect or
confirmed falsified (counterfeit)
• Licence holder/Producer/Importer
• Modus operandi (criminal activity/alteration)
• Distribution path (country of origin-transit-destination)
• Conditions of seizure
• Signal of harm (suspected/confirmed)
• Laboratory results (EDQM/OMCL Network: > 1600 test reports)
François-Xavier Lery © 2015 EDQM, Council of Europe. All rights reserved.
SPOC to liaise with Official Medicines Control or
Reference Laboratories for analytical testing
In Europe, coordinated by EDQM/Council of Europe
SPOC health authorities: evaluation and risk
communication
SPOC customs authorities: circumstances of seizure,
distribution path…
SPOC police/gendarmerie authorities: modus operandi,
criminal organisation, investigation
(Industry contact: support for risk management)
Analyse of closed case by SPOCs:
François-Xavier Lery © 2015 EDQM, Council of Europe. All rights reserved.
Content
1. Practicalities: appointment, nomination
2. Information sharing between SPOCs
3. Risk communication
François-Xavier Lery © 2015 EDQM, Council of Europe. All rights reserved.
Risk communication should be based on
risk evaluation
• On-going work of Committee of Experts on
Minimising public health risks posed by counterfeit
medical products & similar crimes (expert & policy-
making levels): CD-P-PH/CMED (EDQM secretariat)
• Procedure for health risk evaluation (suspect
product )
• Procedure for risk communication
(courtesy of Ruth Mosimann / Sabine Thomas – Swissmedic)
François-Xavier Lery © 2015 EDQM, Council of Europe. All rights reserved.
Approach to evaluation of suspect products
• If possible comparison with reference packaging materials
• In any case look up at :
• Dosage form
• Primary and secondary packaging (appearance, print quality,
colour, typographical errors…)
• logo (falsified logos with graphical differences)
• Product leaflet insert (eg paper sheet frequently too thick);
• Safety features (eg seal)
• expiry date
• lot number (primary and secondary packaging)
François-Xavier Lery © 2015 EDQM, Council of Europe. All rights reserved.
Approach to evaluation of suspect products
Example of factors to be taken into account
• Population of patients
• children, elderly patients, large population (antibiotics,
painkillers, creams...)
• Indications
• chronic diseases (hypertension, diabetes...)
• Route of administration
• subcutaneous, oral, injectable…
François-Xavier Lery © 2015 EDQM, Council of Europe. All rights reserved.
Approach to evaluation of suspect products
Example of factors to be taken into account
Side effects
• Severity: death or terminal illness, disease duration> 2
weeks, mild and reversible adverse reactions
Category of medical product
eg therapeutic index
Origin of the medical product known?
François-Xavier Lery © 2015 EDQM, Council of Europe. All rights reserved.
Approach to evaluation of suspect products
Goal = rating the health risk
e.g. risk mild / moderate / severe
Guidance for SPOCs for how to handle similar
cases reoccuring
François-Xavier Lery © 2015 EDQM, Council of Europe. All rights reserved.
Risk evaluation should allow sound risk
communication
Reactive communication ( upon concrete case) and proactive
communication (awareness of risk/ risk reducing behaviours):
fundamentally different approaches & target audience
What is needed for both types of communication:
• establish procedures
• have a strategy based on hard facts
• define what to communicate and to whom
François-Xavier Lery © 2015 EDQM, Council of Europe. All rights reserved.
Thank you
for your attention
European Directorate
for the Quality of Medicines
& HealthCare (EDQM)
François-Xavier Lery © 2015 EDQM, Council of Europe. All rights reserved.

Weitere ähnliche Inhalte

Andere mochten auch

Korte ketens gelderland 17 5-2016
Korte ketens gelderland 17 5-2016Korte ketens gelderland 17 5-2016
Korte ketens gelderland 17 5-2016Sandra van Kampen
 
Final Portfolio - Community Development
Final Portfolio - Community DevelopmentFinal Portfolio - Community Development
Final Portfolio - Community DevelopmentRebekah Williams
 
Where Park Factors Fail: Case Study of an Extreme Park Effect
Where Park Factors Fail: Case Study of an Extreme Park EffectWhere Park Factors Fail: Case Study of an Extreme Park Effect
Where Park Factors Fail: Case Study of an Extreme Park EffectPeter Bonney
 
Knowldge Mobilization as an Institutional Priority
Knowldge Mobilization as an Institutional PriorityKnowldge Mobilization as an Institutional Priority
Knowldge Mobilization as an Institutional PriorityKMb Unit, York University
 
Media Kit 2016
Media Kit 2016Media Kit 2016
Media Kit 2016Liz Cole
 
Hapalan dalil 1 92
Hapalan dalil 1 92Hapalan dalil 1 92
Hapalan dalil 1 92Feri Septian
 
гиперзвуковой тепловой двигатель для ударных беспилотников и крылатых ракет. ...
гиперзвуковой тепловой двигатель для ударных беспилотников и крылатых ракет. ...гиперзвуковой тепловой двигатель для ударных беспилотников и крылатых ракет. ...
гиперзвуковой тепловой двигатель для ударных беспилотников и крылатых ракет. ...mkril
 
Thermogym - Company Profile - ppt presentation
Thermogym - Company Profile - ppt presentationThermogym - Company Profile - ppt presentation
Thermogym - Company Profile - ppt presentationRachel Arjang
 

Andere mochten auch (12)

Korte ketens gelderland 17 5-2016
Korte ketens gelderland 17 5-2016Korte ketens gelderland 17 5-2016
Korte ketens gelderland 17 5-2016
 
Final Portfolio - Community Development
Final Portfolio - Community DevelopmentFinal Portfolio - Community Development
Final Portfolio - Community Development
 
DRAWING LIST
DRAWING LISTDRAWING LIST
DRAWING LIST
 
Where Park Factors Fail: Case Study of an Extreme Park Effect
Where Park Factors Fail: Case Study of an Extreme Park EffectWhere Park Factors Fail: Case Study of an Extreme Park Effect
Where Park Factors Fail: Case Study of an Extreme Park Effect
 
Knowldge Mobilization as an Institutional Priority
Knowldge Mobilization as an Institutional PriorityKnowldge Mobilization as an Institutional Priority
Knowldge Mobilization as an Institutional Priority
 
Media Kit 2016
Media Kit 2016Media Kit 2016
Media Kit 2016
 
Hapalan dalil 1 92
Hapalan dalil 1 92Hapalan dalil 1 92
Hapalan dalil 1 92
 
гиперзвуковой тепловой двигатель для ударных беспилотников и крылатых ракет. ...
гиперзвуковой тепловой двигатель для ударных беспилотников и крылатых ракет. ...гиперзвуковой тепловой двигатель для ударных беспилотников и крылатых ракет. ...
гиперзвуковой тепловой двигатель для ударных беспилотников и крылатых ракет. ...
 
Thermogym - Company Profile - ppt presentation
Thermogym - Company Profile - ppt presentationThermogym - Company Profile - ppt presentation
Thermogym - Company Profile - ppt presentation
 
Impact Literacy
Impact LiteracyImpact Literacy
Impact Literacy
 
GREEN HRM IN INDIA
GREEN HRM IN INDIAGREEN HRM IN INDIA
GREEN HRM IN INDIA
 
Farrukh cv
Farrukh cvFarrukh cv
Farrukh cv
 

Ähnlich wie 150129 APEC Clark SPOCs

Patients at the Centre of Patient Safety byEPF
Patients at the Centre of Patient Safety byEPFPatients at the Centre of Patient Safety byEPF
Patients at the Centre of Patient Safety byEPFAtlantic Training, LLC.
 
Patients at the Centre of Patient Safety by EPF
Patients at the Centre of Patient Safety by EPFPatients at the Centre of Patient Safety by EPF
Patients at the Centre of Patient Safety by EPFAtlantic Training, LLC.
 
Pharmacovigilance Practice In
Pharmacovigilance Practice InPharmacovigilance Practice In
Pharmacovigilance Practice Inclarityeye
 
EuroBioForum 2013 - Day 2 | Frank Molina
 EuroBioForum 2013 - Day 2 | Frank Molina EuroBioForum 2013 - Day 2 | Frank Molina
EuroBioForum 2013 - Day 2 | Frank MolinaEuroBioForum
 
Mind Your Step : identifying risk with unlicensed medicines
Mind Your Step : identifying risk with unlicensed medicinesMind Your Step : identifying risk with unlicensed medicines
Mind Your Step : identifying risk with unlicensed medicinesSimon Letellier
 
How does France cope with the new expectations of the citizens regarding e-He...
How does France cope with the new expectations of the citizens regarding e-He...How does France cope with the new expectations of the citizens regarding e-He...
How does France cope with the new expectations of the citizens regarding e-He...Fòrum Català d’Informació i Salut
 
Pistoia Alliance European Conference 2015 - Ann Martin / IMI
Pistoia Alliance European Conference 2015 - Ann Martin / IMIPistoia Alliance European Conference 2015 - Ann Martin / IMI
Pistoia Alliance European Conference 2015 - Ann Martin / IMIPistoia Alliance
 
Risk-based approach to infectious disease safety
Risk-based approach to infectious disease safetyRisk-based approach to infectious disease safety
Risk-based approach to infectious disease safetyTGA Australia
 
Quantitative methods of signal detection on spontaneous reporting system data...
Quantitative methods of signal detection on spontaneous reporting system data...Quantitative methods of signal detection on spontaneous reporting system data...
Quantitative methods of signal detection on spontaneous reporting system data...Francois MAIGNEN
 
Pharmacovigilance - Processes & Challenges
Pharmacovigilance - Processes & ChallengesPharmacovigilance - Processes & Challenges
Pharmacovigilance - Processes & Challengespi
 
Introducing Comprehensive, Concurrent Patient Safety Surveillance for Hospita...
Introducing Comprehensive, Concurrent Patient Safety Surveillance for Hospita...Introducing Comprehensive, Concurrent Patient Safety Surveillance for Hospita...
Introducing Comprehensive, Concurrent Patient Safety Surveillance for Hospita...Health Catalyst
 

Ähnlich wie 150129 APEC Clark SPOCs (20)

150128 APEC Clark SPOCs
150128 APEC Clark SPOCs150128 APEC Clark SPOCs
150128 APEC Clark SPOCs
 
Patients at the Centre of Patient Safety byEPF
Patients at the Centre of Patient Safety byEPFPatients at the Centre of Patient Safety byEPF
Patients at the Centre of Patient Safety byEPF
 
Patients at the Centre of Patient Safety by EPF
Patients at the Centre of Patient Safety by EPFPatients at the Centre of Patient Safety by EPF
Patients at the Centre of Patient Safety by EPF
 
Alert and sentinel approaches for the identification of work-related diseases...
Alert and sentinel approaches for the identification of work-related diseases...Alert and sentinel approaches for the identification of work-related diseases...
Alert and sentinel approaches for the identification of work-related diseases...
 
Pharmacovigilance Practice In
Pharmacovigilance Practice InPharmacovigilance Practice In
Pharmacovigilance Practice In
 
ECDC ARHAI networks: achievements in 2013-2014 and challenges for 2015-2016, ...
ECDC ARHAI networks: achievements in 2013-2014 and challenges for 2015-2016, ...ECDC ARHAI networks: achievements in 2013-2014 and challenges for 2015-2016, ...
ECDC ARHAI networks: achievements in 2013-2014 and challenges for 2015-2016, ...
 
An introduction to the EMA
An introduction to the EMAAn introduction to the EMA
An introduction to the EMA
 
THE E-HEALTH PANORAMA by Christian FOURY
THE E-HEALTH PANORAMA by Christian FOURYTHE E-HEALTH PANORAMA by Christian FOURY
THE E-HEALTH PANORAMA by Christian FOURY
 
EuroBioForum 2013 - Day 2 | Frank Molina
 EuroBioForum 2013 - Day 2 | Frank Molina EuroBioForum 2013 - Day 2 | Frank Molina
EuroBioForum 2013 - Day 2 | Frank Molina
 
Mind Your Step : identifying risk with unlicensed medicines
Mind Your Step : identifying risk with unlicensed medicinesMind Your Step : identifying risk with unlicensed medicines
Mind Your Step : identifying risk with unlicensed medicines
 
How does France cope with the new expectations of the citizens regarding e-He...
How does France cope with the new expectations of the citizens regarding e-He...How does France cope with the new expectations of the citizens regarding e-He...
How does France cope with the new expectations of the citizens regarding e-He...
 
Michele bcn02 2007
Michele bcn02 2007Michele bcn02 2007
Michele bcn02 2007
 
Quæfacta GCCCF May 22th, 2019
Quæfacta GCCCF May 22th, 2019Quæfacta GCCCF May 22th, 2019
Quæfacta GCCCF May 22th, 2019
 
Pistoia Alliance European Conference 2015 - Ann Martin / IMI
Pistoia Alliance European Conference 2015 - Ann Martin / IMIPistoia Alliance European Conference 2015 - Ann Martin / IMI
Pistoia Alliance European Conference 2015 - Ann Martin / IMI
 
Risk-based approach to infectious disease safety
Risk-based approach to infectious disease safetyRisk-based approach to infectious disease safety
Risk-based approach to infectious disease safety
 
Quantitative methods of signal detection on spontaneous reporting system data...
Quantitative methods of signal detection on spontaneous reporting system data...Quantitative methods of signal detection on spontaneous reporting system data...
Quantitative methods of signal detection on spontaneous reporting system data...
 
Mez medical virology
Mez medical virologyMez medical virology
Mez medical virology
 
Prof. Dr. Arno Elmer, Managing Director, gematik (Society for Telematics Appl...
Prof. Dr. Arno Elmer, Managing Director, gematik (Society for Telematics Appl...Prof. Dr. Arno Elmer, Managing Director, gematik (Society for Telematics Appl...
Prof. Dr. Arno Elmer, Managing Director, gematik (Society for Telematics Appl...
 
Pharmacovigilance - Processes & Challenges
Pharmacovigilance - Processes & ChallengesPharmacovigilance - Processes & Challenges
Pharmacovigilance - Processes & Challenges
 
Introducing Comprehensive, Concurrent Patient Safety Surveillance for Hospita...
Introducing Comprehensive, Concurrent Patient Safety Surveillance for Hospita...Introducing Comprehensive, Concurrent Patient Safety Surveillance for Hospita...
Introducing Comprehensive, Concurrent Patient Safety Surveillance for Hospita...
 

150129 APEC Clark SPOCs

  • 1. APEC LSIF training program on Medical Products Integrity and Supply Chain Security: Establishment of global SPOC Systems 29 January 2015 François-Xavier Lery, EDQM/Council of Europe Practical tools and approaches for SPOCs François-Xavier Lery © 2015 EDQM, Council of Europe. All rights reserved.
  • 2. Content 1. Practicalities: appointment, nomination 2. Information sharing between SPOCs 3. Risk communication François-Xavier Lery © 2015 EDQM, Council of Europe. All rights reserved.
  • 3. Practicalities of establishment of SPOC network • Competent authorities (1 State): identification & nomination of SPOCs; 1 National SPOC • Network (directory of contact details SPOCs): administration & maintenance, confidentiality, updates • Support tools (SPOC): • Form/data base information exchange among SPOCs/ periodical reports • health risk evaluation procedure (suspect product) • risk communication procedure – awareness campaigns or about a concrete case François-Xavier Lery © 2015 EDQM, Council of Europe. All rights reserved.
  • 4. Context for SPOC appointment François-Xavier Lery © 2015 EDQM, Council of Europe. All rights reserved. …Combatting organised crimes requires: • appropriate powers • responsibility (data confidentiality) • security of SPOCs (national /regional network) • availability: 24/7/365 • access to information/ data (analyses, data bases systematic collection, exchange, sharing of information) Major role in reduction of health risks; involvement in investigation & judicial procedures
  • 5. SPOC Nomination • By Ministries or Heads of Directorates or Agencies: • Fields: • Regulation for Pharmaceuticals • Official Medicines Control Laboratories • Police/ Gendarmerie • Customs (officials only) Note: Industry = reference /contact for support upon request from authorities (case by case) • Nomination Letter: to be issued by senior official • SPOC & deputy SPOC (1 per competent authority) • 1 National SPOC (international cooperation; link with national network of SPOC authorities) François-Xavier Lery © 2015 EDQM, Council of Europe. All rights reserved.
  • 6. Profile of Nominees • Depends on job duties/functions of post held (officials involved in investigations; operational management of cases of crimes affecting medical products) • Professional experience • Contact details of deputy needed • Agreement to share SPOCs contact details with other SPOC nominees • Nomination letter duly signed (original) by Director / Head of Agency • Validity period (unlimited or limited or linked to post) of nomination François-Xavier Lery © 2015 EDQM, Council of Europe. All rights reserved.
  • 7. Nomination • Should authorise to make information available within national network of SPOCs (administrative procedure) • SPOCs should be warned about risks and consequences of non-authorised use of information that should stay within the SPOCs network, or negligent handling of information shared through the network François-Xavier Lery © 2015 EDQM, Council of Europe. All rights reserved.
  • 8. Content 1. Practicalities: appointment, nomination 2. Information sharing between SPOCs 3. Risk communication François-Xavier Lery © 2015 EDQM, Council of Europe. All rights reserved.
  • 9. Receiving & signal handling/collecting information through SPOCs network 1. Signals: handling – see SPOCs toolkit 2. Rapid Alert : suspect medical product Form PIC/S (Pharmaceutical Inspection Convention Pharmaceutical Inspection Cooperation Scheme) Health risk evaluation Communication (professionals / public) 3. Closed cases: Periodic trend analyses (data/signals, reports, results of preventive /coercive measures) - databases e.g. EDQM’s KnowX or other international organisations 4. Feed-back François-Xavier Lery © 2015 EDQM, Council of Europe. All rights reserved.
  • 10. Receiving & signal handling/collecting information through SPOCs (network) Rapid Alert : suspect medical product Example: form PIC/S (Pharmaceutical Inspection Convention Pharmaceutical Inspection Cooperation Scheme) François-Xavier Lery © 2015 EDQM, Council of Europe. All rights reserved.
  • 11. François-Xavier Lery © 2015 EDQM, Council of Europe. All rights reserved.
  • 12. François-Xavier Lery © 2015 EDQM, Council of Europe. All rights reserved.
  • 13. Receiving & signal handling/collecting information through SPOC network Closed case (no Rapid Alert): Periodic trend analyses (data/signals, reports, results of preventive /coercive measures) - databases e.g. EDQM’s KnowX or other international organisations • Medical product description (genuine) – suspect or confirmed falsified (counterfeit) • Licence holder/Producer/Importer • Modus operandi (criminal activity/alteration) • Distribution path (country of origin-transit-destination) • Conditions of seizure • Signal of harm (suspected/confirmed) • Laboratory results (EDQM/OMCL Network: > 1600 test reports) François-Xavier Lery © 2015 EDQM, Council of Europe. All rights reserved.
  • 14. SPOC to liaise with Official Medicines Control or Reference Laboratories for analytical testing In Europe, coordinated by EDQM/Council of Europe SPOC health authorities: evaluation and risk communication SPOC customs authorities: circumstances of seizure, distribution path… SPOC police/gendarmerie authorities: modus operandi, criminal organisation, investigation (Industry contact: support for risk management) Analyse of closed case by SPOCs: François-Xavier Lery © 2015 EDQM, Council of Europe. All rights reserved.
  • 15. Content 1. Practicalities: appointment, nomination 2. Information sharing between SPOCs 3. Risk communication François-Xavier Lery © 2015 EDQM, Council of Europe. All rights reserved.
  • 16. Risk communication should be based on risk evaluation • On-going work of Committee of Experts on Minimising public health risks posed by counterfeit medical products & similar crimes (expert & policy- making levels): CD-P-PH/CMED (EDQM secretariat) • Procedure for health risk evaluation (suspect product ) • Procedure for risk communication (courtesy of Ruth Mosimann / Sabine Thomas – Swissmedic) François-Xavier Lery © 2015 EDQM, Council of Europe. All rights reserved.
  • 17. Approach to evaluation of suspect products • If possible comparison with reference packaging materials • In any case look up at : • Dosage form • Primary and secondary packaging (appearance, print quality, colour, typographical errors…) • logo (falsified logos with graphical differences) • Product leaflet insert (eg paper sheet frequently too thick); • Safety features (eg seal) • expiry date • lot number (primary and secondary packaging) François-Xavier Lery © 2015 EDQM, Council of Europe. All rights reserved.
  • 18. Approach to evaluation of suspect products Example of factors to be taken into account • Population of patients • children, elderly patients, large population (antibiotics, painkillers, creams...) • Indications • chronic diseases (hypertension, diabetes...) • Route of administration • subcutaneous, oral, injectable… François-Xavier Lery © 2015 EDQM, Council of Europe. All rights reserved.
  • 19. Approach to evaluation of suspect products Example of factors to be taken into account Side effects • Severity: death or terminal illness, disease duration> 2 weeks, mild and reversible adverse reactions Category of medical product eg therapeutic index Origin of the medical product known? François-Xavier Lery © 2015 EDQM, Council of Europe. All rights reserved.
  • 20. Approach to evaluation of suspect products Goal = rating the health risk e.g. risk mild / moderate / severe Guidance for SPOCs for how to handle similar cases reoccuring François-Xavier Lery © 2015 EDQM, Council of Europe. All rights reserved.
  • 21. Risk evaluation should allow sound risk communication Reactive communication ( upon concrete case) and proactive communication (awareness of risk/ risk reducing behaviours): fundamentally different approaches & target audience What is needed for both types of communication: • establish procedures • have a strategy based on hard facts • define what to communicate and to whom François-Xavier Lery © 2015 EDQM, Council of Europe. All rights reserved.
  • 22. Thank you for your attention European Directorate for the Quality of Medicines & HealthCare (EDQM) François-Xavier Lery © 2015 EDQM, Council of Europe. All rights reserved.